Efficacy and Safety of Diclofenac + Capsaicin Gel in Patients with Acute Back/Neck Pain: A Multicenter Randomized Controlled Study
Rattachement africain : de, fr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Back and neck pain are common musculoskeletal disorders. Topical non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used to reduce pain and inflammation with fewer systemic side effects and drug interactions compared with oral NSAIDs. This study assessed efficacy and tolerability of a topical combination of capsaicin + diclofenac to treat acute back/neck pain. In a randomized, double-blind, controlled, multicenter, parallel group trial, 746 patients were treated twice-daily for 5 days with diclofenac 2% + capsaicin 0.075%, diclofenac 2%, capsaicin 0.075% or placebo. Efficacy assessments included change and area under the curve in pain on movement for the worst procedure (POM WP ), change in pressure algometry, and number of patients with decrease in POM WP of ≥ 30% and ≥ 50%. Adverse events (AEs) were recorded. Change in POM WP between baseline and day 2 evening, 1 h after drug application, demonstrates superiority of the combination (− 3.05 cm) versus diclofenac alone (− 2.33 cm) and placebo (− 2.45 cm), but not capsaicin alone (− 3.26 cm). AEs were consistent with known safety profiles. Capsaicin alone and capsaicin + diclofenac showed superior benefit compared with placebo. However, diclofenac alone demonstrated efficacy comparable with placebo, and therefore its addition to capsaicin added no increased pain relief over capsaicin alone. ClinicalTrials.gov identifier; NCT02700815.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Efficacy and Safety of Diclofenac + Capsaicin Gel in Patients with Acute Back/Neck Pain: A Multicenter Randomized Controlled Study
- Date Crossref
- 27/03/2020
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
German Sport University Cologne Institute for Cardiology and Sports Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Sanofi (France) pays non établi dans la noticeEntreprise
-
Boehringer Ingelheim (Germany) pays non établi dans la noticeEntreprise
-
Sanofi (Germany) pays non établi dans la noticeEntreprise
-
Consumer Health Care pays non établi dans la noticeInstitution
-
Boehringer Ingelheim Pharma GmbH & Co KG pays non établi dans la noticeEntreprise
-
Sanofi-Aventis Deutschland GmbH Medical Affairs pays non établi dans la noticeEntreprise
Institute for Cardiology and Sports Medicine — German Sport University Cologne, Sanofi (France) et Boehringer Ingelheim (Germany), avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.